SCHEMBL926774

SCHEMBL926774

COc1ccc(-c2cc(=O)c3cc(NC(C)=O)ccc3o2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 3/20 0.72
▸ CSNK2B P67870 3/20 0.72
▸ CSNK2A1 P68400 3/20 0.72
▸ MAPT P10636 8/20 0.68
▸ TP53 P04637 7/20 0.68
▸ CYP3A4 P08684 5/20 0.68
▸ ALDH1A1 P00352 5/20 0.68
▸ KDM4E B2RXH2 4/20 0.68
▸ HPGD P15428 4/20 0.68
▸ NPC1 O15118 3/20 0.68
▸ RAB9A P51151 3/20 0.68
▸ HSD17B10 Q99714 3/20 0.68
▸ RXFP1 Q9HBX9 3/20 0.68
▸ NFKB1 P19838 2/20 0.68
▸ NFKB2 Q00653 2/20 0.68
▸ RELA Q04206 2/20 0.68
▸ LMNA P02545 2/20 0.68
▸ THRB P10828 2/20 0.68
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ MEN1 O00255 4/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7637766 0.89 MAPT (0.67) CSNK2A2CSNK2BCSNK2A1MAPTTP53
Hydrochloric Acid SCHEMBL926266 0.87 MAPT (0.64) CSNK2A2CSNK2BCSNK2A1MAPTTP53
SCHEMBL17786371 0.87 CSNK2A2 (0.69) CSNK2A2CSNK2BCSNK2A1MAPTTP53
SCHEMBL17786567 0.86 CSNK2A2 (0.61) CSNK2A2CSNK2BCSNK2A1MAPTTP53
SCHEMBL17786530 0.85 CSNK2A2 (0.65) CSNK2A2CSNK2BCSNK2A1MAPTTP53
SCHEMBL17786578 0.84 CSNK2A2 (0.64) CSNK2A2CSNK2BCSNK2A1MAPTTP53
SCHEMBL17786417 0.82 CSNK2A2 (0.62) CSNK2A2CSNK2BCSNK2A1MAPTTP53
6,4'-Dimethoxyflavone SCHEMBL4281291 0.82 MAPT (1.00) CSNK2A2CSNK2BCSNK2A1MAPTTP53
6,4'-Dimethoxyflavone SCHEMBL29478471 0.82 MAPT (1.00) CSNK2A2CSNK2BCSNK2A1MAPTTP53
SCHEMBL21884870 0.81 MAPT (0.78) CSNK2A2CSNK2BCSNK2A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016083490-A1 COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES REMYND NV (BE) 2016-06-02 — — WO disclosed
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 — — US disclosed
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 — — US disclosed
EP-2268628-B1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM SPA (IT) 2012-05-16 — — EP disclosed
EP-2268628-B1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM SPA (IT) 2012-05-16 — — EP disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 — — US disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 — — US disclosed
EP-2268628-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN Rottapharm S.p.A. (IT) 2011-01-05 — — EP disclosed
WO-2009109230-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2009-09-11 — — WO disclosed
WO-2009109230-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN NAT1, AADAC, OPRL1 CSNK2A2 1153/4885CSNK2B 2039/4885CSNK2A1 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback